文献速递心力衰竭与心肌病

乳腺癌幸存者射血分数保留型心力衰竭的叙述性综述

A narrative review of heart failure with preserved ejection fraction in breast cancer survivors.
PubMed 文献 · Heart · 2023-07-27

本文为叙述性综述,总结乳腺癌幸存者中射血分数保留型心力衰竭(HFpEF)的风险、机制与管理。作者指出近期研究提示乳腺癌后 HFpEF 是更常见的亚型,其风险与治疗相关毒性及共享危险因素有关,社会健康决定因素亦可能参与;临床应提高对 HFpEF 的警觉并筛查心血管危险因素。

要点

  • 乳腺癌幸存者 HFpEF 风险升高,近期研究提示其为乳腺癌后更常见的心衰亚型。
  • 治疗相关毒性与共享危险因素共同驱动 HFpEF 风险。
  • 对该高危人群筛查心血管危险因素(尤其高血压)可能有益。

核心结论

  • 乳腺癌幸存者中 HFpEF 风险升高且疾病负担显著,但该人群 HFpEF 研究不足。

研究设计与样本

  • 叙述性综述,聚焦乳腺癌幸存者射血分数保留型心力衰竭。

主要发现

  • 多数研究聚焦乳腺癌后射血分数降低型心力衰竭(HFrEF),但近期研究提示 HFpEF 是乳腺癌后更常见的心衰亚型。
  • 乳腺癌幸存者 HFpEF 风险升高可能与治疗相关毒性及同时增加乳腺癌与 HFpEF 风险的共享危险因素有关。
  • 除高血压、肥胖等有生理影响的危险因素外,社会健康决定因素(SDOH)可能影响乳腺癌后 HFpEF 的诊断、管理与预后。

临床怎么用

  • 提高对乳腺癌后 HFpEF 的临床警觉,并对该高危人群筛查心血管危险因素,尤其高血压。
  • 乳腺癌幸存者发生 HFpEF 时,治疗重点是启动指南导向药物治疗,并通过药物或行为干预处理基础合并症。

局限性

  • 乳腺癌幸存者中的 HFpEF 研究不足;未来需深入理解其病因、阐明相关危险因素及发病机制。
  • 未来需明确不同乳腺癌治疗方式(如放疗、化疗、生物治疗及内分泌治疗如芳香化酶抑制剂)与 HFpEF 的关联。
  • 需刻画 SDOH 与这些治疗如何交互,以制定预防与管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in breast cancer (BC) treatment have contributed to improved survival, but BC survivors experience significant short-term and long-term cardiovascular mortality and morbidity, including an elevated risk of heart failure with preserved ejection fraction (HFpEF). Most research has focused on HF with reduced ejection fraction (HFrEF) after BC; however, recent studies suggest HFpEF is the more prevalent subtype after BC and is associated with substantial health burden. The increased HFpEF risk observed in BC survivors may be explained by treatment-related toxicity and by shared risk factors that heighten risk for both BC and HFpEF. Beyond risk factors with physiological impacts that drive HFpEF risk, such as hypertension and obesity, social determinants of health (SDOH) likely contribute to HFpEF risk after BC, impacting diagnosis, management and prognosis.Increasing clinical awareness of HFpEF after BC and screening for cardiovascular (CV) risk factors, in particular hypertension, may be beneficial in this high-risk population. When BC survivors develop HFpEF, treatment focuses on initiating guideline-directed medical therapy and addressing underlying comorbidities with pharmacotherapy or behavioural intervention. HFpEF in BC survivors is understudied. Future directions should focus on improving HFpEF prevention and treatment by building a deeper understanding of HFpEF aetiology and elucidating contributing risk factors and their pathogenesis in HFpEF in BC survivors, in particular the association with different BC treatment modalities, including radiation therapy, chemotherapy, biological therapy and endocrine therapy, for example, aromatase inhibitors. In addition, characterising how SDOH intersect with these therapies is of paramount importance to develop future prevention and management strategies.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Yogeswaran, Wadden, Szewczyk, et al. A narrative review of heart failure with preserved ejection fraction in breast cancer survivors. Heart. 2023. PMID: 37258098. doi:10.1136/heartjnl-2022-321859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。